PL1885342T3 - Inhibitor krystalizacji i jego zastosowanie w kapsułkach żelatynowych - Google Patents

Inhibitor krystalizacji i jego zastosowanie w kapsułkach żelatynowych

Info

Publication number
PL1885342T3
PL1885342T3 PL06738862.9T PL06738862T PL1885342T3 PL 1885342 T3 PL1885342 T3 PL 1885342T3 PL 06738862 T PL06738862 T PL 06738862T PL 1885342 T3 PL1885342 T3 PL 1885342T3
Authority
PL
Poland
Prior art keywords
gelatin capsules
crystallization inhibitor
crystallization
inhibitor
capsules
Prior art date
Application number
PL06738862.9T
Other languages
English (en)
Inventor
Tomas Andrysek
Ales Vrana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1885342(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL1885342T3 publication Critical patent/PL1885342T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
PL06738862.9T 2005-03-21 2006-03-16 Inhibitor krystalizacji i jego zastosowanie w kapsułkach żelatynowych PL1885342T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66482605P 2005-03-21 2005-03-21

Publications (1)

Publication Number Publication Date
PL1885342T3 true PL1885342T3 (pl) 2016-10-31

Family

ID=36675980

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06738862.9T PL1885342T3 (pl) 2005-03-21 2006-03-16 Inhibitor krystalizacji i jego zastosowanie w kapsułkach żelatynowych

Country Status (10)

Country Link
US (1) US8673351B2 (pl)
EP (1) EP1885342B8 (pl)
CN (1) CN101141953A (pl)
CO (1) CO6321129A2 (pl)
ES (1) ES2573539T3 (pl)
HU (1) HUE029192T2 (pl)
IL (1) IL185729A0 (pl)
MX (1) MX2007011250A (pl)
PL (1) PL1885342T3 (pl)
WO (1) WO2006102157A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271088A1 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
CN101721931B (zh) * 2009-11-26 2012-08-08 广州普正生物科技有限公司 一种多相混悬系统及其制备方法与应用
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
WO2013144976A2 (en) * 2012-03-28 2013-10-03 Medreich Limited Chewable soft gelatin capsule dosage form of mucolytic agents
WO2015022349A1 (en) * 2013-08-14 2015-02-19 Ratiopharm Gmbh Dosage form comprising enzalutamide
CN107106644B (zh) * 2014-11-07 2022-04-15 卓越治疗有限公司 包含环孢菌素的组合物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113544117A (zh) * 2019-02-06 2021-10-22 埃默拉尔德健康制药公司 大麻二酚衍生物的调配物和其作为2型大麻素受体（cb２）的调节剂的用途
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
AU609242B2 (en) 1988-01-29 1991-04-26 Novartis Ag Cyclosporin compositions
FR2683225B1 (fr) 1991-10-31 1993-12-31 Gattefosse Sa Procede pour ameliorer une huile glycerolysee.
DE4221491C2 (de) * 1992-06-29 1994-09-29 Pohl Boskamp Gmbh Chem Pharma Verfahren zur Herstellung von Weichgelatinekapseln
ATE398448T1 (de) * 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH10211425A (ja) * 1997-01-29 1998-08-11 Fuji Capsule Kk カプセルの乾燥方法
CO4940469A1 (es) * 1997-03-05 2000-07-24 Sugen Inc Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2326485C (en) * 1998-04-01 2008-12-09 Rtp Pharma Inc. Anticancer compositions
JP3500313B2 (ja) * 1998-10-27 2004-02-23 花王株式会社 カプセル粒子の水分除去方法
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
AU2001289438A1 (en) * 2000-09-22 2002-04-02 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391472B (en) * 2002-08-02 2004-12-08 Satishchandra Punambhai Patel Pharmaceutical compositions
US7025911B2 (en) * 2002-09-13 2006-04-11 Freund Corporation Manufacturing method for oral quick-dissolving seamless capsule
JP2004262774A (ja) * 2003-02-20 2004-09-24 Freunt Ind Co Ltd シームレスカプセル
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone

Also Published As

Publication number Publication date
WO2006102157A1 (en) 2006-09-28
EP1885342A1 (en) 2008-02-13
US20110020438A1 (en) 2011-01-27
ES2573539T3 (es) 2016-06-08
EP1885342B8 (en) 2016-06-22
IL185729A0 (en) 2008-01-06
MX2007011250A (es) 2007-11-14
US8673351B2 (en) 2014-03-18
CO6321129A2 (es) 2011-09-20
HUE029192T2 (en) 2017-02-28
EP1885342B1 (en) 2016-03-09
CN101141953A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
IL185729A0 (en) Crystallization inhibitor and its use in gelatin capsules
EP1747299A4 (en) DEVICES AND METHODS USING ONE-CRYSTAL FORM MEMORY ALLOYS
IL185280A0 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
ZA200709854B (en) 17ß-HSD1 and STS inhibitors
EP1951680A4 (en) NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
EP1731506A4 (en) 5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
EP1920216A4 (en) SIGNALING AND LOCATION ORIENTATION
ZA200710817B (en) Benzamide derivatives and uses related thereto
GB0512940D0 (en) Compounds and their use
IL190955A0 (en) Dicarboxylic acid derivatives and their use
HK1101911A1 (en) Tetrahydrocarbozoles and derivatives
HK1122988A1 (en) Proteasome inhibitors and uses thereof
GB0516069D0 (en) Pharmaceutical and use thereof
GB0520743D0 (en) Compounds and their use
PT2380575E (pt) Acetato de eslicarbazepina e utilização
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
IL189252A0 (en) Dihydroxyanthraquinones and their use
ZA200805386B (en) MIF inhibitors
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF
GB0603717D0 (en) Electricity-generate and store
GB0411257D0 (en) Cassette and its use
EP2074999A4 (en) USE OF RUBESCENSIN A AND ITS DERIVATIVES IN PHARMACY
EP1866723A4 (en) DEVICE FOR REDUCING RISK WHEN SELLING A PROPERTY
GB2425708B (en) Bracelet and use thereof
GB0506249D0 (en) Pharses and word